GRI

GRI Bio Inc

Jan 29 • 04:00PM ET

3.32

-0.79 -19.22 %

Healthcare • Biotechnology • USA • NASD

Today, 11:02 AMGRI Bio stock plunges 21.33% despite positive Phase 2a gene expression data for IPF treatment.

Peers: GILD BMY LLY AZN VRTX AMGN REGN BIIB MRNA IONS

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-440.54	Insider Own	31.16%	Shs Outstand	0.54M	Perf Week	-39.57%
Market Cap	1.78M	Forward P/E	-	EPS next Y	-48.86	Insider Trans	0.00%	Shs Float	0.37M	Perf Month	-52.17%
Enterprise Value	-2.19M	PEG	-	EPS next Q	-29.26	Inst Own	0.90%	Short Float	6.76%	Perf Quarter	-93.89%
Income	-13.16M	P/S	-	EPS this Y	89.37%	Inst Trans	3.17%	Short Ratio	0.08	Perf Half Y	-94.22%
Sales	0.00M	P/B	0.19	EPS next Y	70.35%	ROA	-219.61%	Short Interest	0.03M	Perf YTD	-51.96%
Book/sh	17.07	P/C	0.44	EPS next 5Y	80.04%	ROE	-397.84%	52W High	333.20 -99.00%	Perf Year	-98.89%
Cash/sh	7.57	P/FCF	-	EPS past 3/5Y	90.45% 70.23%	ROIC	-650.32%	52W Low	3.87 -14.21%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	23.86% 20.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	98.22%	Oper. Margin	-	ATR (14)	1.75	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.70	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	21.36	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.70	EPS Q/Q	88.78%	SMA20	-48.55%	Beta	-1.41	Target Price	644.00
Payout	-	Debt/Eq	0.04	Sales Q/Q	-	SMA50	-85.50%	Rel Volume	1.75	Prev Close	4.11
Employees	4	LT Debt/Eq	0.02	Earnings	Nov 12	SMA200	-91.75%	Avg Volume	300.43K	Price	3.32
IPO	Feb 10, 2021	Option/Short	No / No	EPS/Sales Surpr.	-15.32% -	Trades		Volume	526,309	Change	-19.22%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-24	Initiated	H.C. Wainwright	Buy	$10

Jan-28-26 08:45AM	GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF (GlobeNewswire) -22.74%
Jan-26-26 08:30AM	GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures (GlobeNewswire)
Jan-21-26 04:01PM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) -12.02%
Jan-08-26 08:00AM	GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621 (GlobeNewswire)
Dec-12-25 04:05PM	GRI Bio Announces Closing of $8.0 Million Public Offering (GlobeNewswire) -10.04%
09:15AM	Loading…
Dec-11-25 09:15AM	GRI Bio Announces Pricing of $8,000,000 Million Public Offering (GlobeNewswire) -56.45%
Dec-10-25 04:05PM	GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") (GlobeNewswire) -12.95%
Sep-11-25 08:45AM	GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") (GlobeNewswire) +31.41%
Sep-03-25 09:00AM	GRI Bio to Present at the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 09:15AM	GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (GlobeNewswire) +10.77%
Jul-31-25 01:50PM	GRI Bio CEO, Marc Hertz, Participates in Virtual Investor "What This Means" Segment (GlobeNewswire) -37.56%
09:00AM	GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") (GlobeNewswire)
Jul-22-25 08:45AM	GRI Bio Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (GlobeNewswire)
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-01-25 08:45AM	GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF") (GlobeNewswire) +6.20%
10:54AM	Loading…
Jun-30-25 10:54AM	GRI Bio reports six-week interim safety outcomes from trial of GRI-0621 for IPF (Clinical Trials Arena)
Jun-26-25 08:00AM	GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") (GlobeNewswire) -5.19%
May-22-25 08:00AM	GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results (GlobeNewswire) -9.42%
May-21-25 09:15AM	GRI Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire)
May-16-25 09:15AM	GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase (GlobeNewswire)
May-15-25 08:35AM	GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 (GlobeNewswire)
May-08-25 08:45AM	GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") (GlobeNewswire) -10.61%
May-07-25 09:15AM	GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF") (GlobeNewswire) -6.28%
Apr-16-25 08:35AM	GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference (GlobeNewswire)
Apr-02-25 04:05PM	GRI Bio Announces Closing of $5.0 Million Public Offering (GlobeNewswire) -17.33% -13.77%
01:38PM	GRI Stock Down on Public Offering Despite Encouraging IPF Study Data (Zacks)
Apr-01-25 11:15AM	GRI Bio Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -36.87%
09:00AM	GRI Bio Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire)
Mar-31-25 08:00AM	GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan (GlobeNewswire) -26.71%
Mar-18-25 09:05AM	GRI Bio Participates in a Virtual Investor CEO Connect Segment (GlobeNewswire) +16.01%
08:05AM	Loading…
Mar-17-25 08:05AM	GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -6.18%
Mar-11-25 08:35AM	GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule (GlobeNewswire) -5.24%
Feb-19-25 04:05PM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) -17.90%
09:00AM	GRI Bio, Inc. Participates in the Virtual Investor Top 5 for '25 On-Demand Conference (GlobeNewswire)
Dec-23-24 09:00AM	GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds (GlobeNewswire)
Dec-06-24 08:35AM	GRI Bio to Participate in the Virtual Investor Closing Bell Series (GlobeNewswire) +21.73%
Nov-21-24 08:45AM	GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire) +7.82%
Nov-14-24 04:20PM	GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis (GlobeNewswire) +9.12% -19.57%
Oct-24-24 08:30AM	GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024 (GlobeNewswire)
Oct-21-24 05:35PM	GRI Bio Announces Exercise of Warrants (GlobeNewswire) +127.59% -26.52%
Oct-16-24 08:45AM	GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire) +25.43%
Oct-07-24 08:30AM	GRI Bio to Present at the 22nd International Colloquium on Lung and Airway Fibrosis (GlobeNewswire)
Sep-30-24 08:30AM	GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions (GlobeNewswire) -19.06%
Sep-26-24 08:00AM	GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia (GlobeNewswire) +6.00%
Sep-25-24 08:45AM	GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment (GlobeNewswire)
Sep-18-24 09:00AM	GRI Bio Participates in Virtual Investor KOL Connect Segment (GlobeNewswire)
Sep-05-24 08:45AM	GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Sep-04-24 08:45AM	GRI Bio to Present at the 2024 European Respiratory Congress (GlobeNewswire)
Aug-14-24 08:05AM	GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire) -7.57%
Jul-15-24 09:05AM	GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
Jul-11-24 09:20AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor What This Means Segment (GlobeNewswire)
Jul-08-24 09:05AM	GRI Bio Regains Compliance with Nasdaq (GlobeNewswire)
Jul-02-24 09:05AM	GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine (GlobeNewswire) -13.68%
Jul-01-24 08:45AM	GRI Bio to Present at the 8th Annual IPF Summit (GlobeNewswire)
Jun-28-24 04:05PM	GRI Bio Announces Closing of $4.0 Million Public Offering (GlobeNewswire)
Jun-27-24 09:00AM	GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators (GlobeNewswire) +7.10%
08:00AM	GRI Bio Announces Pricing of $4 Million Public Offering (GlobeNewswire)
Jun-26-24 08:23AM	Why Is GRI Bio (GRI) Stock Down 29% Today? (InvestorPlace) -38.38%
07:41AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace)
Jun-24-24 07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-17-24 08:00AM	Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024 (ACCESSWIRE)
Jun-14-24 08:05AM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) -11.90%
Jun-12-24 04:15PM	Connect Biopharma Announces New Leadership and Chair of the Board of Directors (GlobeNewswire)
Jun-11-24 09:00AM	GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference (GlobeNewswire)
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE)
May-23-24 10:30AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect (ACCESSWIRE) -9.03%
May-22-24 09:15AM	GRI Bio (NASDAQ: GRI) Participates in Virtual Investor What This Means Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs (GlobeNewswire) +9.53%
May-21-24 08:35AM	GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE) (GlobeNewswire)
May-20-24 08:45AM	GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) (GlobeNewswire)
May-14-24 09:05AM	GRI Bio to Present at Alliance Global Partner's 2024 Healthcare Company Showcase (GlobeNewswire)
May-13-24 10:54AM	GRI Stock Earnings: GRI Bio Reported Results for Q1 2024 (InvestorPlace)
08:00AM	GRI Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-29-24 08:45AM	GRI Bio Announces Abstracts Accepted for Presentation at the 14th International Congress on Autoimmunity (GlobeNewswire)
Apr-25-24 09:15AM	GRI Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (GlobeNewswire)
Apr-16-24 08:35AM	GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent (GlobeNewswire)
Apr-08-24 08:35AM	GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference (GlobeNewswire) +5.16%
Apr-01-24 07:35AM	GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-28-24 09:00AM	GRI Bio to Present at the MedInvest Biotech & Pharma Investor Conference (GlobeNewswire)
Mar-14-24 08:45AM	GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators (GlobeNewswire)
Mar-04-24 08:30AM	GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom (GlobeNewswire)
Feb-02-24 08:55AM	Why Is GRI Bio (GRI) Stock Down 21% Today? (InvestorPlace) -26.15%
08:00AM	GRI Bio Announces Pricing of $5.5 Million Public Offering (GlobeNewswire)
Jan-26-24 08:05AM	GRI Bio Announces Reverse Stock Split (GlobeNewswire) +5.62%
Dec-06-23 01:47PM	GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment (News Direct) -5.98%
Dec-05-23 09:05AM	GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -25.39%
Nov-27-23 08:35AM	GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT ( iNKT ) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis ( IPF ) (GlobeNewswire) -13.33%
Nov-15-23 08:05AM	GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -6.49%
Oct-31-23 08:45AM	GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases (GlobeNewswire) +5.17%
Oct-19-23 08:45AM	GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference (GlobeNewswire)
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) -5.47%
Oct-17-23 08:35AM	GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression (GlobeNewswire) -14.09%
Oct-11-23 09:05AM	GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference (GlobeNewswire)
Oct-05-23 08:45AM	GRI Bio Announces Publication of Comprehensive Invariant NKT (iNKT) Cell Review in Frontiers in Immunology Demonstrating a Key Role of Type 1 iNKT Cells in Modulating Various Fibrotic Conditions (GlobeNewswire)
Sep-29-23 09:00AM	September Is Pulmonary Fibrosis Awareness Month: Heres What One Company Is Doing To Develop A Treatment For This Deadly Disease (ACCESSWIRE) -6.91%
Sep-06-23 09:05AM	GRI Bio to Present at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Sep-01-23 09:15AM	IPF Has A 0% Survival Rate Without Lung Transplant And A Median Survival Time Of 2-5 Years From Diagnosis - Could GRI-0621 Be The Solution? (ACCESSWIRE)
Aug-29-23 11:06AM	GRI Bio Engages B2i Digital to Deploy Cutting-Edge Engagement Campaign (Newsfile) +5.74%
Aug-25-23 09:00AM	GRI Bio Is Bringing Hope To Patients With Idiopathic Pulmonary Fibrosis And Lupus (ACCESSWIRE) -12.26%
Aug-23-23 09:00AM	GRI Bio Enters into Asset Purchase Agreement with Aardvark Therapeutics, Inc. for the Sale of Legacy Asset, ADAIR (GlobeNewswire) -25.75%
Aug-16-23 12:00PM	JTC Team Announces the Launch of the Virtual Investor "What This Means" On Demand Video Series (ACCESSWIRE)

GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GRI

GRI Bio Inc

Upgrade your FINVIZ experience